Amerikaanse aandelen « Terug naar discussie overzicht

Forum Transenterix geopend

344 Posts, Pagina: « 1 2 3 4 5 6 ... 8 9 10 11 12 13 14 15 16 17 18 » | Laatste

Omlaag ↓

kevkeg 28 mei 2019 13:35

Senhance is goedgekeurd in Japan

ir.transenterix.com/news-releases/new...

[verwijderd] 28 mei 2019 13:45

quote:
kevkeg schreef op 28 mei 2019 13:35:
Senhance is goedgekeurd in Japan

ir.transenterix.com/news-releases/new...

Prima bericht!

[verwijderd] 28 mei 2019 22:38

Herstel is matig; verwacht morgen nog wel een stevige stijging. Sta nog diep in het rood!

[verwijderd] 29 mei 2019 09:24

Eerst maar eens terug naar 3 dollar!

RW1963 3 juni 2019 19:35

Persoonlijk hecht ik er weinig waarde aan. Maar Marktgevoel tipt dit aandeel deze maand wel.

[verwijderd] 5 juni 2019 11:40

quote:
RW1963 schreef op 3 juni 2019 19:35:
Persoonlijk hecht ik er weinig waarde aan. Maar Marktgevoel tipt dit aandeel deze maand wel.

Alles is meegenomen.

[verwijderd] 5 juni 2019 11:41

Nu nog wat verkopen!

kevkeg 10 juli 2019 20:15

ir.transenterix.com/news-releases/new...

kevkeg 26 juli 2019 00:01

ir.transenterix.com/news-releases/new... Cijfers Q2 op 7 augustus.

[verwijderd] 8 augustus 2019 14:19

Zo zeg, deze gaat lekker door het putje vanweg de slechte Q2 cijfers!

BC Capital downgraded the stock from Outperform to Sector Perform and lowered its price target from $3 to $1 per share

RIP

DeZwarteRidder 8 augustus 2019 16:14

quote:
DeZwarteRidder schreef op 13 oktober 2018 14:33:
Dit aandeel is belachelijk duur en loopt lichtjaren vooruit op winst die misschien nooit gemaakt zal worden.

OoooJeee.....!!!

Een koersdoel van 1 $.....!!!

Wie had dat nou verwacht....????

DeZwarteRidder 9 augustus 2019 15:50

TransEnterix, Inc. Reports Operating and Financial Results for the Second Quarter 2019
August 7, 2019 at 4:05 PM EDT

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aug. 7, 2019-- TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the second quarter of 2019.

Recent Highlights

Total revenue of $3.6 million in the second quarter of 2019
Received Japanese regulatory approval of the Senhance® Surgical System
Received broad Japanese reimbursement for 98 different procedures, effective July 31, 2019
AutoLap asset sale and equity sale to bring in a total of $47 million

“While we were disappointed with our system sales in the quarter, we are encouraged by our operational accomplishments including the monetization of the AutoLap assets and achievement of Japanese regulatory approval and broad reimbursement well ahead of our expectations,” said Todd M. Pope, President, and CEO of TransEnterix. “We are focused on improving commercial execution to drive global system sales in the second half of the year.”

Commercial and Clinical Update

In the quarter ended June 30, 2019, the Company sold one Senhance® System, in the EMEA region to an end user hospital.

On May 28, 2019, the Company announced that it received Japanese regulatory approval for the Senhance Surgical System. The Senhance Surgical System was approved by the Ministry of Health, Labor and Welfare (MHLW) for use in laparoscopy for general surgery, gynecology, and urology.

On August 1, 2019, the Company announced that the MHLW expert review panel provided reimbursement for procedures performed with the Senhance Surgical System. The reimbursement, which became effective on July 31, 2019, applies to 98 benign and malignant laparoscopic surgeries at reimbursement rates equivalent to traditional laparoscopy in Category A1.

AutoLap Asset Sale

On July 10, the Company announced the sale of certain AutoLap® image-based laparoscope positioning system (AutoLap) product and intellectual property assets to Great Belief International Limited (GBIL). The total proceeds to be paid to the Company for these assets is $17 million. In addition, GBIL is making an equity investment of $30.0 million in TransEnterix common stock at $2.00 per share. As a part of the sale agreement, the Company retains ownership of the broader intellectual property portfolio it acquired from M.S.T. - Medical Surgery Technologies in October 2018, and will enter into a cross-license agreement with GBIL under which it gains a license to use the AutoLap-related IP sold, and grants GBIL a non-exclusive license to use additional IP in connection with the AutoLap.

Second Quarter Financial Highlights

For the three months ended June 30, 2019, the Company reported revenue of $3.6 million as compared to revenue of $6.4 million in the three months ended June 30, 2018. Revenue in the second quarter of 2019 included $2.7 million in system sales, $560 thousand in instruments and accessories, and $342 thousand in services. The $2.7 million in system sales revenue includes the recognition of $1.3 million from a system sold in 2017 for which revenue was deferred until its first clinical use, which occurred in the second quarter.

For the three months ended June 30, 2019, total net operating expenses were $22.2 million, as compared to $18.5 million in the three months ended June 30, 2018.

For the three months ended June 30, 2019, net loss was $20.2 million, or $0.09 per basic share, as compared to a net loss of $34.2 million, or $0.17 per basic share, in the three months ended June 30, 2018.

For the three months ended June 30, 2019, adjusted net loss was $19.2 million, or $0.09 per basic share, as compared to an adjusted net loss of $11.7 million, or $0.06 per basic share in the three months ended June 30, 2018, after adjusting for the following charges: change in fair value of warrant liabilities, amortization of intangible assets, change in fair value of contingent consideration, loss on debt extinguishment, acquisition-related costs and the loss (gain) on the sale of the SurgiBot assets. Adjusted net loss is a non-GAAP measure. See the reconciliation to GAAP below.

The Company had cash and cash equivalents, restricted cash and short term investments of approximately $34.0 million as of June 30, 2019. The Company believes that existing cash and short term investments and the expected proceeds from the AutoLap transaction are sufficient to support the business into mid-2020.

Conference Call

TransEnterix, Inc. will host a conference call on Wednesday, August 7, 2019, at 4:30 p.m. ET to discuss its second quarter 2019 operating and financial results. To listen to the conference call on your telephone, please dial (844) 804-5261 for domestic callers or (612) 979-9885 for international callers and reference conference ID 4293967 approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link ir.transenterix.com/events.cfm. The replay will be available on the Company's website.

About TransEnterix

TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment. The Company is focused on the commercialization of the Senhance® Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU, and select other countries. For more information, visit www.transenterix.com.

prrrrr 6 september 2019 07:11

rt 0.75 pffffffffffffff

[verwijderd] 6 september 2019 07:25

quote:
Transenterix56 schreef op 10 mei 2019 21:04:
Zuid-Duitsland + geheel nieuwe techniek, meer kan ik echt niet zeggen!!!

Weet je inmiddels al wat meer?

DeZwarteRidder 6 september 2019 08:59

quote:
Jager63 schreef op 6 september 2019 07:25:
[...]
Weet je inmiddels al wat meer?

Die T-figuur is een bedrieger.

veer62 6 september 2019 12:42

Dezwarteridder wil jij je oog laten vallen op kbsf.alvast bedankt

[verwijderd] 9 september 2019 07:25

quote:
Transenterix56 schreef op 16 april 2019 11:23:
Heeft iets langer geduurd als gewenst maar heb informatie ontvangen inmiddels. Ik kan niet exact aangeven wat de ontwikkelingen zijn maar we kunnen als longers rustig blijven zitten. Zelfs nog iets bijkopen als mogelijk is. Ik kijk relaxed de toekomst tegen moet. Als alles gerealiseerd wordt zijn er spectaculaire ontwikkelingen te verwachten!!!!

Licht eindelijk eens een tipje van de sluier op!!!!

DeZwarteRidder 9 september 2019 07:27

quote:
veer62 schreef op 6 september 2019 12:42:
Dezwarteridder wil jij je oog laten vallen op kbsf.alvast bedankt

Ik heb geen idee wat dat is.

DeZwarteRidder 9 september 2019 07:27

quote:
Jager63 schreef op 9 september 2019 07:25:
[...]
Licht eindelijk eens een tipje van de sluier op!!!!

T-figuur is een oplichter.

[verwijderd] 11 september 2019 08:06

Wie biedt er wat voor deze hut?

344 Posts, Pagina: « 1 2 3 4 5 6 ... 8 9 10 11 12 13 14 15 16 17 18 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 884,07 0,00 0,00% 15 apr


Germany40^	17.893,90	-0,74%
BEL 20	3.853,74	0,00%
Europe50^	4.942,69	-0,84%
US30^	37.698,66	0,00%
Nasd100^	17.693,66	0,00%
US500^	5.060,86	0,00%
Japan225^	38.697,76	0,00%
Gold spot	2.386,97	+0,16%
EUR/USD	1,0612	-0,12%
WTI	85,06	0,00%